Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus

Despite the decreasing morbidity associated with the human immunodeficiency virus (HIV), a large percentage of persons with HIV have at least 1 drug resistance mutation. Ibalizumab, a recently approved drug, targets multidrug-resistant HIV. We present a case of reactivation of hepatitis B after init...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, Alyson, DeHaan, Elliott, Maltz, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443835/
https://www.ncbi.nlm.nih.gov/pubmed/34549064
http://dx.doi.org/10.14309/crj.0000000000000594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443835/
https://www.ncbi.nlm.nih.gov/pubmed/34549064
http://dx.doi.org/10.14309/crj.0000000000000594

Ejemplares similares